Immutep Limited announced the last patient has been enrolled in the expansion stage of Part A of its Phase II TACTI-002 study (also designated KEYNOTE-798). The Company announced that the TACTI-002 study has completed recruitment of patients across all cohorts. A total of 185 patients are now participating in TACTI-002 across Parts A, B, and C at 20 clinical sites in Australia, Europe, and the US. Notably, recruitment into the expansion stage of Part A was completed faster than anticipated, with all patients in this stage being recruited in under 12 months.